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INTRODUCTION 
 
The classification of renal cell neoplasms includes numerous entities 
characterized by different prognosis and the correct subtyping is one of the most 
important procedures to predict the behavior of these tumors.1-5 Clear cell renal cell 
carcinoma (RCC) that in 20% of cases shows metastases at the time of the diagnosis 
and in 30-40% develops metastases during the follow up period, represents the 
majority of renal cell tumors. However, other renal cell carcinomas with lower 
malignancy or benign renal cell neoplasms can occur. Due to overlapping 
morphological features and the increasing recognition of novel entities6, the histologic 
distinction of renal cell neoplasms is becoming challenging or sometime insufficient. 
That is why traditional histology needs today the support of more specific tools 
making the correct classification more and more feasible and reproducible. Different 
subtypes of renal cell tumors are identified by specific molecular markers that often 
represent the most reliable aspect of them and sometime the unique specific feature7. 
Several markers have been proposed as distinctive features suggesting a role of the 
protein expression profile and cytogenetic pattern in the recognition and classification 
of renal cell tumors.7-10 Since paraffin embedded tissue is the most diffuse available 
material in pathology laboratories, the immunohistochemistry and fluorescence in situ 
hybridization analyses have become the most powerful tools able to obtain the protein 
and cytogenetic expression profiling of these neoplasms.  
Moreover, targeted therapies, such as the novel tyrosine kinase inhibitors 
Sunitinib and Sorafenib have been approved by the Food and Drug Administration as 
having significant clinical activity in metastatic clear cell renal cell carcinoma.11  
Different types of renal epithelial neoplasms have been described in 
association with end-stage renal disease, with a high prevalence of papillary renal cell 
2 
carcinomas and clear cell renal cell carcinomas.12-20 However, tumors arising in 
kidneys involved by end-stage renal diseases may also show distinctive histologic 
features not easily classified according to the current WHO classification system.21-23 
In 2006 two distinctive renal carcinomas have been described in the spectrum of 
epithelial neoplasms in end-stage renal disease. The most common was designated as 
“acquired cystic disease associated renal carcinoma” and the second as “clear-cell 
papillary renal cell carcinoma of the end-stage kidneys”. The latter is a tumor 
composed mainly of cells with clear cytoplasm arranged in cystic and papillary 
patterns.23 
Acquired cystic disease-associated renal cell carcinoma is generally positive 
for vinculin and parvalbumin and showed a strong and diffuse immunoexpression for 
AMACR, whereas CK7 was negative.23 Cossu-Rocca et al. found that eosinophilic 
renal cell tumors associated with acquired cystic disease have genetic profiles distinct 
from the renal cell neoplasms recognized in the current classification. They showed 
no losses or gains of chromosomes 1, 2, 6, 10, or 17 in one tumor and gains of 
chromosomes 1, 2, and 6 in other two tumors.24 Recently, O'Reilly et al described in 
abstract form FISH analyses with centromeric probes for chromosomes 1, 3, 7 and 17 
on 10 tumors arising in end-stage renal disease, among which two acquired cystic 
kidney disease-associated tumors were included. They found that both tumors were 
disomic for chromosomes 1 and 3, whereas one had loss of chromosome 7 and the 
other showed loss of chromosome 17.25  
Clear-cell papillary renal cell carcinoma of the end-stage kidney described by 
Tickoo et al., unlike papillary RCC, were constantly negative for AMACR, but unlike 
clear-cell RCC all tumors tested showed strong immunoexpression for CK7.23  
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In 2008 we found similar results studying clear-cell papillary renal cell 
carcinomas arising in normal kidneys. We observed also the positive immunoreaction 
for CA9 and the lack of immunoexpression of CD10 and TFE3. Cytogenetically, 
clear-cell papillary renal cell carcinomas were characterized by the absence of the 
typical chromosomal aberrations found in papillary RCC (trisomy of chromosome 7 
and 17 and loss of chromosome Y) or in clear cell RCC (deletion of chromosome 
3p).26  
These findings let us to identify clear cell-papillary RCC as a Distinct 
Histopathological and Molecular Genetic Entity. 
Macroscopically, clear cell papillary renal cell carcinomas showed a variable 
cystic and solid morphology; some tumors exhibit a predominantly solid and white-
mahogany brown appearance. The histologic features of these tumors comprise 
morphologic changes that are typical of both clear cell renal cell carcinoma and 
papillary renal cell carcinoma. Despite their diffusely papillary architecture, these 
tumors are entirely composed of cells with clear cytoplasm. In contrast to classic clear 
cell renal cell carcinoma, these tumors lack a delicate sinusoidal vascular network. 
Their architecture is papillary, but in contrast to classic papillary renal cell 
carcinomas, the tumor cells exhibit optically clear cytoplasm. Aggregates of foamy 
macrophages in the stroma of the papillary cores and areas of cholesterol cleft 
formation, findings often seen in classic type 1 papillary renal cell carcinoma, are not 
observed in these tumors. The differential diagnosis may be difficult, considering that 
clear cell renal cell carcinoma can show pseudopapillary architecture, and papillary 
renal cell carcinoma may exhibit components of cells with clear cytoplasm. However, 
pseudopapillae in clear cell renal cell carcinoma are usually only focally present, and 
papillary renal cell carcinomas with extensive clear changes are rare.27,28 In the latter 
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the cytoplasmic clearing is typically partial with some degree of granularity 
remaining. Clear cell-papillary RCC show encapsulation with variable architectural 
patterns consisting in papillae occurring within tubules and cysts, branching tubules 
similar to benign prostatic acini, and tubulo-glandular structures of variable sizes and 
shape. Variable sized cysts can be also present, predominantly at the periphery of the 
tumor. All tumor cells have clear cytoplasm with nuclei aligned away from the basal 
membrane, resembling secretory endometrium. The nuclei of all cases are 
predominantly low grade (ISUP nucleolar grade 1-2), with only focal areas showing 
prominent nucleoli. The stroma is hyalinized although  occasionally 
fibroleiomyomatous areas can be also seen.  
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Figure 1. Clear cell-papillary renal cell carcinoma; gross appearance. 
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Figure 2. Clear cell-papillary renal cell carcinoma; microscopic appearance. 
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Figure 3. Clear cell-papillary renal cell carcinoma; A: immunoexpression of CK7; B: 
negative for CD10 (positive in the normal parenchyma); C: immunoexpression of 
CAIX.  
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DESIGN 
The aim of my study is to better understand the molecular pattern of clear cell-
papillary RCC looking for a possible specific marker that can make its diagnosis more 
reproducible and well distinctive from the more frequent clear cell RCC and papillary 
RCC. 
First of all I propose a review of histological and molecular pattern of clear cell RCC 
and papillary RCC that are the most frequent renal cell carcinomas (80% and 15%) 
and that are the two entities considered in the differential diagnosis of clear cell-
papillary RCC. 
To validate immunohistochemical and FISH results we suggest to test sections 
containing also normal renal parenchyma adjacent to the neoplasia.  
In normal adult kidney, CD10 stains the glomerular epithelium, Bowman's 
capsule and the normal proximal tubular cells, which shows a strong surface 
membrane staining.29 Parvalbumin is constantly and strongly expressed, with a 
cytoplasmic and nuclear pattern, in a variable number of cells of distal convoluted 
tubules, connecting tubules, and in a subset of collecting duct cells, likely intercalated 
cells.30 Strong diffuse cytoplasmic expression of cytokeratin 7 is observed within the 
cells of the distal tubules and collecting ducts of the non-neoplastic kidney.31,32 Renal 
parenchyma displays cytoplasmic and/or a nuclear immunostaining for S100A1 in the 
cells lining proximal tubules, loops of Henle, collecting ducts, and Bowman's 
capsule.33 AMACR immunoreactivity is present in proximal convoluted renal tubules, 
but very minimal to absent in distal tubules, glomeruli, medullary tubules and stromal 
cells.34 
Few reports regarding FISH analysis showed the fluorescent count on normal 
renal parenchyma. This important issue, due probably to the procedures variability, 
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should be always taken as references from which statistical analysis can extrapolate 
standardized FISH results. It has been reported percentages of single signals, greater 
than 26, 27, 22, 26, and 30% for respectively chromosomes 1, 2, 6, 10, and 17 using a 
non-confocal microscope.35 In normal epithelial cells in the renal tubules, nuclei with 
three or four centromeric signals were occasionally seen but in no sample exceeded 
12% of the total. 36-38   
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Clear cell renal cell carcinoma 
Clear cell RCC is immmunohistochemically characterized by a high positive 
rate for CD10 (82%).29,39,40  In our experience also CD13 is a good 
immunohistochemical marker of clear cell renal cell carcinoma being positive in 81%.41 
Expression of CD15 and S100A1 protein has been reported respectively in 75% and 
73% of the cases.33,42 Most clear cell RCCs typically shows a restricted expression 
pattern of cytokeratins (CK) with limited cases expressing CK8, CK19 and high weight 
CKs, a large portion of cases positive for CK18 and only 6% of the cases expressing 
CK7.43-45 Around more than a half of clear cell RCCs reveals immunoreactivities for 
RCC marker, Epithelial Membrane Antigen (EMA) and vimentin.39,40,43,46 Alpha-
methylacyl-CoA racemase (AMACR) reactivity has been detected in 13 of 52 (25%) 
and c-kit in 1 of 40 (3%) whereas parvalbumin was found to be constantly absent.30,34,47 
Moreover, clear cell RCCs are infrequently positive for BerEP4 (27%), MOC31 (4%) 
and E-Cadherin (5%)40,45,48. Carbonic anhydrase 9 (CA9) is a protein iperexpressed in 
hypoxia condition and is induced through the signaling pathway involving VHL gene 
and HIF-alfa. The immunoexpression of CA9 is positive in clear cell RCCs and a 
prognostic value has been proposed.49,50  
Membranous pattern of immunoexpression of caveolin-1 has been observed to be 
specific of clear cell RCC.51  
Mutation of the Von Hippel-Lindau syndrome (VHL) gene mapping in the 
chromosomal region 3p25 occurs almost exclusively in this type of renal tumor. 
Moreover, loss of heterozygosis has been observed among 3p14, 3p21.3 and 3p25 
both in sporadic and hereditary forms.52 Probably for that reason, clear cell RCC 
cytogenetically shows a highly specific deletion of chromosome 3p that can be easily 
detected in 76% of clear cell RCCs using dual-labeling fluorescence in situ 
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hybridization analysis.53 Cytogenetical studies using commercial available probes for 
the centromere 3 and telomere 3p, analyzing the relative depletion of 3p signals, well 
identify clear cell RCC.26  
Other chromosomal aberrations observed in these tumors are copy number 
gains or losses of 5q21 that is thought to be events that lead to tumor progression, 
even if this finding has not been confirmed.54 Loss of chromosome 14q that has been 
shown to have a close correlation with higher stage, higher histologic grade and 
poorer outcome,55 and loss of chromosome 9p observed in 18% of clear cell RCC as 
an independent negative prognostic factor.56  
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Figure 4: Clear cell renal cell carcinoma. A: macroscopic appearance. B: microscopic 
appearance of conventional case. C: pseudopapillary pattern. D: immunoexpression of 
CD10. E: immunoexpression of CAIX. F: FISH, deletion of 3p. G: molecular alteration 
of the gene VHL.  
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Papillary renal cell neoplasms 
Most papillary RCCs typically express CK7 (87%), 8, 18 and 19, and vimentin 
(90%).43,57 CK7 expression is more frequently observed in type 1 (87-100%) than type 
2 (20-50%)58 such as EMA (type 1 ranging from 72 to 100% and type 2 from 13 to 
17%)46,59 whereas E-cadherin is reported predominantly in type 2.46 Both type 1 and 
type 2 papillary RCCs constantly show AMACR immunostain.34,60 An high incidence 
of positivity for BerEP4 (67%), RCC Marker (63%)61 and CD10 (59-90%)29,40 is 
reported. S100A1 and CD15 are respectively observed in 92% and 41% of papillary 
RCCs33,42 which occasionally express high molecular weight CKs (26%) and MOC31 
(11%).40  
Chromosomal aberrations occur early in the evolution of papillary renal cell 
neoplasia also in small tumors of a few millimeters in diameter with trisomy of 
chromosomes 7, 17 and loss of the Y chromosome as the most consistent genetic 
abnormalities. Additional chromosomal gains are observed and some authors suggest 
they characterize the progression from papillary adenomas to papillary RCC.9,36,62-64 
Some authors have suggested genetic differences between the two morphological types 
(type 1 and type 2) of papillary RCCs: type 1 cases seem to have a significantly higher 
frequency of allelic imbalance on 17q and type 2 cases an higher frequency of allelic 
imbalance on 9p.65  
Oncocytic papillary RCC, considered a third group of papillary RCCs with a different 
outcome, has been reported to carry three or more signals for chromosome 7 and 17 
like type 1 and type 2 papillary RCCs.62,66 
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Figure 5: Papillary renal cell carcinoma. A: macroscopic appearance. B: microscopic 
appearance of conventional case. C: cytoplasmic clarification. D: immunoexpression 
of AMACR. E: immunoexpression of cytokeratin (CK) 7. F: FISH, trisomy of 
chromosome 7 and chromosome 17. 
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MATERIAL AND METHODS 
Immunohistochemical Staining 
Immunohistochemistry was performed with the following antibodies 
(summarized in table 1): cytokeratin 7 (CK7) (DAKO, Carpintera ,CA; clone OV-TL 
12/30; prediluted); CD10 (Nova- castra, Burlingame, CA, USA; clone 56C6; 1:10 
dilution); alpha-methylacyl-CoA racemase (AMACR) (P504S) (Dako; clone 13H7; 
1:50 dilution); carbonic anhydrase IX (CAIX) (Abcam Inc, Cambridge, MA; clone 
ab1508; 1:1000 dilution); GATA3 (BD Pharmingen, San Diego, CA, clone L50-823, 
1:50 dilution) CD10 (Nova- castra, Burlingame, CA, USA; clone 56C6; 1:10 
dilution); cytokeratin 5 (Novacastra; clone XM26; 1:100 dilution); cytokeratin 
34bE12 (Dako, Carpinteria, CA, USA; clone 34bE12; 1:40 dilution); cytokeratin 14 
(Biogenex; clone LL002; 1:50 dilution); cytokeratin 1 (Novacastra; clone 34βB4; 
1:50 dilution); cytokeratin 10 (Novacastra; clone 2HP1; 1:50 dilution); SLC2A1 
(GLUT1) (Dako; polyclonal, rabbit; 1:100 dilution); vimentin (Biogenex; clone V9; 
1:50 dilution); S100A1 (Dako; clone S100A1/1; 1:50 dilution); a-smooth muscle actin 
(Dako; clone 1A4; 1:250 dilution); HMB45 (Dako; clone HMB45; 1:300 dilution) 
and cathepsin K (Abcam, Cambridge, UK; clone 3F9; 1:2000 dilution).  Briefly, 
slides were deparaffinized twice in xylene for 5 min and rehydrated through graded 
ethanol solutions to distilled water. Antigen retrieval was performed by heating 
sections in citrate buffer, EDTA buffer, or enzymatically with proteinase K. 
Inactivation of endogenous peroxidase activity was obtained by incubating sections in 
3% H2O2 for 15 min. Localization of bound antibodies was performed with 
peroxidaselabeled streptavidin–biotin system (DAKO, LSAB2 Kit) with 3,3’-
diaminobenzidine as a chromogen. Appropriate positive controls for each antibody 
were run concurrently and showed adequate immunostaining. Normal renal 
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parenchyma adjacent to the tumors was used as a control. A total of 442 cases of 
conventional clear cell renal cell carcinoma were used as control for our 
immunohistochemical analysis: 180 cases as whole sections and the remaining 262 
distributed on 8 tissue microarrays including 221 primary carcinomas and 41 
metastatic carcinomas. 
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Antigen   Clone   Dilution   Company 
CK7   OV-TL12/30  
1:500  
 
  Biogenex, Fremont, CA, USA 
CD10   56C6   1:10    Novacastra, Burlingame, CA, USA 
AMACR   13H7   1:25   Dako, Carpinteria, CA, USA 
CAIX  Policlonale   1:1000  Abcam, Cambridge, UK 
SLC2A1 (GLUT1)  Policlonale   1:100  Dako, Carpinteria, CA, USA 
34βE12  34βE12  1:40  Dako, Carpinteria, CA, USA 
CK14  LL002  1:50  Biogenex, Fremont, CA, USA 
CK5  XM26  1:100  Novacastra, Burlingame, CA, USA 
CK1  34βB4  1:50  Novacastra, Burlingame, CA, USA 
CK10  2HP1  1:50  Novacastra, Burlingame, CA, USA 
GATA3  L50-823  1:150  BD Pharmingen, San Diego, CA, USA 
S100A1   S100A1/1   1:50    Dako, Carpinteria, CA, USA 
HMB45  HMB45  1:300  Dako, Carpinteria, CA, USA 
Catepsina K  3F9  1:2000  Abcam, Cambridge, UK 
Vimentina   V9   1:50    Biogenex, Fremont, CA, USA 
Actin SM   1A4   1:250    Dako, Carpinteria, CA, USA 
 
Table 1: Antigens used for the immunohistochemical analyses.  
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Fluorescence In Situ Hybridization 
Series of 4 m slides were prepared from buffered formalin fixed, paraffin 
embedded tissue blocks. The slides were deparaffinized with two washes of xylene, 
15 min each, and subsequently washed twice with absolute ethanol, 10 min each and 
then air dried in the hood. Next, the slides were treated with 0.1mM citric acid (pH 
6.0) (Zymed, CA, USA) at 95°C for 10 min, rinsed in distilled water for 3 min 
followed by a wash of 2×SSC (standard saline citrate) for 5 min. Digestion of the 
tissue was performed by applying 0.4 ml of pepsin (5 mg/ml in 0.1N Hcl/0.9 NaCl) 
(Sigma, St Louis, MO, USA) at 37°C for 40 min. The slides were rinsed with distilled 
water for 3 min, washed with 2×SSC for 5 min and air dried. FISH was performed 
with centromeric -satellite DNA probes for chromosome 7 (CEP 7, Spectrum 
Green), 17 (CEP 17, Spectrum Orange), Y (CEP Y, Spectrum Green), 3 (CEP3, 
Spectrum Orange) and subtelomeric probe for 3p25 (3pTel25, Spectrum Green). All 
of the probes were from Vysis (Downers Grove, IL, USA) and were diluted with 
tDenHyb1 (CEP 7-CEP 17 and CEP Y) and tDenHyb 2 (CEP 3-3pTel25) (Insitus, 
Alburquerque, NM, USA) in a ratio of 1:100, respectively. 5 l of diluted probe was 
applied to each slide in reduced light conditions. The slides were then covered with a 
22×22mm cover slip and sealed with rubber cement. Denaturation was achieved by 
incubating the slides at 83°C for 12 min in a humidified box and hybridization at 
37°C overnight. The cover slips were removed and the slides were washed twice with 
0.1XSSC/1.5M urea at 45°C (20 min for each), followed by a wash with 2×SSC for 
20 min and with 2×SSC/0.1% NP-40 for 10 min at 45°C. The slides were further 
washed with room temperature 2×SSC for 5 min. The slides were air dried and 
counterstained with 10 l DAPI (Insitus, Albuquerque, NM, USA), covered with 
cover slips and sealed with nail polish.38,67,68The slides were examined using a Zeiss 
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Axioplan 2 microscope (ZEISS, Gottingen, Germany) with the following filters from 
Chroma (Chroma, Brattleboro, VT, USA): SP-100 DAPI, FITC MF-101 for Spectrum 
Green (CEP 7, Y and 3pTel25) and Gold 31003 for Spectrum Orange (CEP 3 and 17). 
The images were acquired with a CCD camera and analyzed with MetaSystem Isis 
Software (MetaSystem, Belmont, MA, USA). Five sequential focus stacks with 0.4 
mm intervals were acquired and then integrated into a single image in order to reduce 
thickness-related artifacts. 
We performed fluorescence in situ hybridization analysis with the same 
probes (CEP 7, 17, 3 and 3pTel25) in classic clear cell renal cell carcinoma and 
classic papillary renal cell carcinoma as controls. 
 
In Situ Hybridization Analysis 
The method of analysis was partially described previously.9,35,69,70 In brief, for 
each slide, 100 to 150 nuclei from tumor tissue were scored for signals from probes 
under the fluorescence microscope with ×1000 magnification. Non-neoplastic kidney 
parenchyma was used as control. Definitions of chromosomal gain and loss of 
chromosomes 7, 17 and Y were based on the Gaussian model and related to the non-
neoplastic controls. Any tumor with the signal score beyond the cutoff value was 
considered to have gain or loss of specific chromosome. The cutoff values for each 
probe were set at mean plus three standard deviations (S.D.) of the control values. 
Statistical method to analyze 3p deletion was referred to previous studies on deletion 
of chromosome 1p and 19q in oligodendrogliomas.71 The cutoff value for the 3/3p 
ratio was set at mean plus three standard deviations (S.D.) of the 3/3p ratio in non-
neoplastic cells. Any tumor with 3/3p ratio beyond the cutoff values was considered 
to have deletion of 3p25. 
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Array Comparative Genomic Hybridization and Data Analysis 
Microdissection from the three formalin-fixed paraffin-embedded kidney tumors was 
performed manually, with accurate attention in obtaining material from the epithelial 
zones of tissue slides. 
Genomic DNA was isolated using the QIAamp DNA mini kit (Qiagen Nordic, 
Finland) and quanti- fied on the NanoDrop spectrophotometer (NanoDrop 
Technologies Inc, DE, USA). As a reference, we used DNA from pooled peripheral 
blood leukocytes of healthy males. Using the Agilent Human 244K array format 
containing B240 000 oligonucleotide probes, covering both coding and non-coding 
genome re- gions (Agilent Technologies, Santa Clara, CA, USA), we screened copy 
number alterations in all three tumors. Briefly, 1.5mg of tumor and reference DNA 
were digested, labelled, and hybridized according to the Agilent protocols. The array 
images obtained after scanning (Agilent scanner G2565BA) were processed with the 
Feature Extraction software (version 10.5), and the output data files were analyzed 
with the Agilent Genomic Workbench. To identify copy number alterations, we used 
aberration detection method 2 (ADM-2) algorithm and to exclude the small variances 
in the data, we set up a custom aberration filter identifying alterations in copy number 
if a minimum of eight probes gained or lost were identified and with a minimum 
absolute average log ratio for the region being 0.5. Regions with small copy number 
variations were excluded by comparing and visualizing the copy number variant 
regions tool of the Genomic Workbench software. 
ch fluorescent score number. 
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VHL sequencing analysis 
Five 10-μm thick sections of tumor tissue were cut from formalin-fixed 
paraffin-embedded blocks. Epithelial and smooth muscle components were separated 
by manual microdissection. DNA was extracted separately from each component. 
Polymerase chain reaction (PCR) for VHL gene analysis was performed using primer 
sequences as reported.72,73  Normal tissues from the same patients were used as a 
reference. The reaction conditions were as follows: 12.5 μl of HotStart Taq PCR 
Master Mix (QIAgen, Hilden, Germany), 10 pmol of each primer, 100 ng of template 
DNA, and distilled water up to 25 μl. Amplification program for all fragments, except 
the marker D3S666, consisted of denaturation at 95°C for 15 min, then 40 cycles of 
denaturation at 95°C for 1 min, annealing at 55°C for 1 min, and extension at 72°C 
for 1 min. The program was finished by 72°C incubation for 7 min. Annealing 
temperature for fragment D3S666 was 58°C. PCR products of the VHL gene were 
purified with Montage PCR Centrifugal Filter Devices (Millipore, Billerica, MA, 
USA) and sequenced using a Big Dye Terminator Sequencing kit (PE/Applied 
Biosystems, Foster City, CA, USA). Samples were then run on an automated 
sequencer ABI Prism 310 (PE/Applied Biosystems) at a constant voltage of 11.3 kV 
for 20 min. PCR products of STR markers were mixed with a size marker and run on 
an automated sequencer ABI Prism 310 (PE/Applied Biosystems) at a constant 
voltage of 15 kV for 28 min. Genomic DNA was isolated from three 5μM- thick 
paraffin sections of each renal carcinoma sample using the Ex-Wax DNA Extraction 
Kit (Chemicon International, Temecula, CA, USA) according to manufacturer 
instructions. Bidirectional sequencing of PCR products was performed by using a 
ABI PRISM BigDye terminators v3.1 cycle sequencing kit (Applied Biosystems, 
Foster City, CA, USA), and sequences were run on an Applied Biosystems 3130 
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Genetic Analyzer (Applied Biosystems) and compared with the reference sequence 
CCDS 2597.1. The PCR amplicon carrying the mutation was subcloned into a 
pGEM®-T Easy vector (Promega, Madison, WI), transformed in competent DH5α 
cells and plated onto LB agar with ampicillin and X-gal selection. Then, 12 distinct 
blank (white) colonies were chosen, plasmid DNA was extracted and submitted for 
amplification and sequencing of VHL exon 3 as described above. 
 
Methylation-specific multiplex ligation-dependent probe amplification (MS–MLPA) 
and CpG methylation analysis 
Microdissection of tissues from formalin-fixed paraffin-embedded kidney tumors was 
performed manually. Genomic DNA extracted from the three samples was subjected 
to MS-MLPA using ME001-0808-C1 and ME002-0809-B1 probemixes (MRC-
Holland, Amsterdam, The Netherlands) with 20-100 ng of DNA per sample. The 
standard MS-MLPA-protocol was employed.74 Both probemixes contained one 
specific MLPA probe for the exon 1 of VHL gene that has a recognition site for a CpG  
methylation-sensitive endonuclease HhaI. The MS-MLPA product fragments were 
analyzed by a ABI model 3130 capillary sequencer (Applied Biosystems, 
Nieuwerkerk aan den Ijssel, the Netherlands) using Genescan-ROX 500 size 
standards. As the same probemixes are intended to detect both copy number and 
methylation changes of the target genes simultaneously, both methylation and copy 
number status was analysed using Coffalyser software (MRC-Holland, Amsterdam, 
The Netherlands)75. The data were first normalized by dividing the peak area of a 
single probe by a cumulative peak area of all control probes (not degraded by HhaI). 
Then, the normalized peaks from the HhaI digestion reaction were compared to the 
normalized peaks from the undigested control reaction. Final methylation value for 
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each sample was obtained by subtracting the background methylation values of the 
control samples (male and female DNA samples, Promega, WI, USA). The following 
criteria were used for determining the methylation status: 0.00-0.25 (absent), 0.25-
0.50 (mild), 0.50-0.75 (moderate), and > 0.75 (extensive methylation). For copy 
number analysis the following cut-off values were used: <0.7 and >1.3 gain. One 
DNA sample (labelled 8656) was excluded from the analysis due to the low amount 
of DNA and for another sample (labelled 10684) we were able to include only results 
using ME002-0809-B1 probemix as no DNA was available for the further analysis 
using the ME-001-0808 mix. 
 
RNA extraction 
In each case, a representative formalin fixed paraffin embedded (FFPE) tissue sample 
was chosen for RNA extraction. Ten unstained slides 8μm thick were cut from blocks 
and a sterile scalpel was used to microdissect tumor cells (80 % or more) after 
deparaffinization with xylene and ethanol washing.  Total RNA was extracted using 
the RecoverAll Total Nucleic Acid Isolation (Ambion Inc., Austin, TX, USA) 
according to manufacturer’s protocol. RNA quantity was measured by using 
NanoDrop Spectrophotometer ND-1000. RNA quality was evaluated using 
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA).  
 
Microarray hybridization 
Four matched tumor and normal samples constituted our discovery set and were 
submitted for microarray analysis. This was performed using the Human miRNA 
Microarray Kit Release 16.0, 8x60K (G4870A, Agilent Technologies, Santa Clara, 
CA) according to  manufacturer’s protocols. The array contains 1205 human 
24 
microRNAs from the Sanger database v16.0 
(http://microrna.sanger.ac.uk/sequences/). Only samples with 28S/18S>1.2, RIN>8 
and detectable miRNA were used for the analysis.  
Microarray hybridization was performed at Sidney Kimmel Cancer Center Microarray 
Core Facility at Johns Hopkins University using manufacture’s instruction as 
previously described76 . Data were acquired with Agilent Feature Extraction 9.5.3.1 
software for miRNA microarray. Two data files are generated for each array: Feature 
Extraction file contains signal intensities from all individual probes and GeneView 
file contains summarized signal intensities for each miRNA by combining intensities 
of replicate probes and background subtraction.  
 
Technical validation of microarray data 
Individual TaqMan microRNA assays (Applied Biosystems, Austin, TX) were used 
for validation of microarray findings in the above discovery set of 4 cases as well as 
11 additional cases (validations set). The individual miRNAs were selected among the 
miRNAs that showed to be the most differentially expressed in the microarray 
experiments. RNU6B was used as reference gene for normalization. Total RNA (10 
ng) was reverse transcribed using TaqMan MicroRNA Reverse Transcription Kit 
(Applied Biosystems, Austin, TX). qRT-PCR was performed using TaqMan 
Universal Master Mix II (Applied Biosystems, Austin, TX) on a 7900HT Fast Real 
Time PCR System according to the manufacturer’s protocol. All samples were run in 
triplicate. Normalized signal levels for each miRNA were calculated using 
comparative cycle threshold method (ΔΔCT method)77. 
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Statistical Analysis 
MicroRNA expression data was processed for statistical analysis using 
packages from R/Bioconductor (www.bioconductor.org) as previously described 78-80. 
Briefly, a generalized linear model was fit for each miRNA to estimate expression 
differences between clear cell papillary tumor and normal kidney, and an empirical 
Bayesian approach was employed to moderate standard errors of expression fold-
change. Multiple testing corrections were performed using the Benjamini-Hochberg 
method. In order to identify consensus of differentially regulated miRNA between 
renal carcinoma histologic types, we additionally determined differential miRNA 
expression using two publically available microarray datasets from the NCBI Gene 
Expression Omnibus (GEO) database (GSE41282 and GSE3798). In these two 
datasets we identified the miRNA expression profiles that distinguish the different 
tumor groups from normal counterparts.  The meta-analysis was performed by 
comparing the lists of differentially expressed miRNA between the groups of interest 
independently obtained from each analyzed dataset with a false discovery rate of 5% 
or less. We also performed comparisons between pairs of data sets using 
Correspondence At the Top plots (CAT-plots), and evaluated the number of 
concordant overlapping genes using Venn diagrams.  CAT-plot confidence intervals 
and probabilities of observing the identified number of concordant overlapping genes 
in the Venn diagrams by chance alone were based on the hyper-geometric 
distribution, as previously described78-80. 
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RESULTS 
 
Immunohistochemical findings 
GATA3 was expressed by 7/13 (54%) clear cell papillary renal cell 
carcinomas. Cases that stained positive for GATA3 showed expression of the marker 
in a percentage of cells variable from 10% to 90% (mean 47%). All cases showed a 
diffuse positivity for cytokeratin 7 in 70-100% of cells. CK AE1-AE3 expression was 
seen in 100% of the neoplastic cells in all cases. SLC2A1 (GLUT1) and CAIX 
displayed variable intensity of expression in all and in all but one case, respectively. 
Cytokeratin 34βE12 and CK14 showed an equivalent pattern of staining as they were 
expressed in the same 12 cases (12/14, 86%). CK1 and CK10 were constantly 
negative while CK5 showed positivity in 4 cases. Alpha-methylacyl-CoA racemase 
(P504S), HMB-45, cathepsin k, androgen receptor, and estrogen and progesterone 
receptors were constantly negative.  S100A1 was expressed in 9/13 cases (1 case was 
not available), while parvalbumin showed weak immunoreactivity in 10% of the 
neoplastic cells in one case. 
The stroma of the tumors showed focal positivity for alpha-smooth muscle 
actin in 12/14 cases (85%). 
Only 2/150 CCRCC cases (1%) of the TMAs stained weakly positive for 34βE12 and 
CK14. 
We previously stained the same 150 conventional clear cell renal cell carcinomas for 
CK7 and found it positive in 36/150 (24%) of the cases. 
In our cohort of conventional clear cell renal cell carcinomas GATA3 positivity was 
seen in only 1/292 (0,3%) of cases that included whole slides of 180 primary 
carcinomas and TMA spots of 71 primary 41 metastatic carcinomas. 
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n. CK7 CD10 AMACR CAIX GLUT-1 S100A1 HMB45 CAT K VIM ACT SM 34βE12 CK14 CK5 CK1 CK10 GATA3 
1 80 neg neg 50 50 neg neg neg neg 60 60 30 neg neg neg neg 
2 100 10 neg 60 30 neg neg n.a. neg 70 100 60 80 neg neg neg 
3 70 70 neg 10 80 10 neg neg neg 10 neg neg neg neg neg neg 
4 80 neg neg 90 90 30 n.a. neg neg 30 20 40 neg neg neg neg 
5 90 40 neg 40 40 50 neg neg neg 60 80 40 30 neg neg 60 
6 80 neg neg 30 50 neg neg n.a. neg 10 neg neg neg neg neg neg 
7 100 neg neg 50 70 n.a. neg n.a. 70 30 80 60 neg neg neg 40 
8 100 neg neg n.a. n.a. 60 neg neg n.a. neg 80 80 neg neg neg 80 
9 90 neg neg 30 70 neg neg neg neg neg 30 30 neg neg neg 60 
10 90 neg neg 60 90 10 neg neg neg 30 60 20 neg neg neg 30 
11 90 10 neg 90 70 70 neg neg neg 70 90 60 10 neg neg 10 
12 70 40 neg 90 60 60 neg neg 20 80 80 70 neg neg neg neg 
13 80 50 neg 90 60 90 n.a. neg neg 40 80 50 10 neg neg 10 
14 70 10 neg 90 50. 80 n.a. neg neg 70 30 20 neg neg neg neg 
 
Table 2: Immunohistochemical results. 
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Figure 6. Pattern of immunoexpression of GATA3 in normal parenchyma. 
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Figure 7. Nuclear immunoexpression of GATA3 in clear cell-papillary renal cell 
carcinoma. 
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Figure 8. Pattern of immunoexpression of 34βE12 and CK14 in normal renal 
parenchyma. 
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Figure 9. Immunoexpression of 34βE12 and CK14 in clear cell-papillary renal cell 
carcinoma. 
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Array Comparative Genomic Hybridization Findings 
Array comparative genomic hybridization was performed in 4 cases of clear cell 
papillary renal cell carcinoma. We did not observe any gene copy number 
abnormalities. A flat profile was observed in each tumor. 
 
 
Figure 10: CGH results. Chromosome 3, flat profile.  
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Fluorescence in situ hybridization (FISH) findings 
Locus specific sub-telomeric 3p probe: For clear cell papillary renal cell 
carcinomas, the average of the cases showed single, double and three or more 
fluorescent signals respectively in of 31%, 62% and 7% of neoplastic epithelial nuclei. 
Centromeric chromosome 3 probe: For clear cell papillary renal cell carcinomas, the 
aberage of cases showed single, double and three or more fluorescent signals 
respectively in 28%, 63% and 9% of neoplastic epithelial nuclei. The value of the ratio 
of the normal renal parenchyma+3SD set to 1,03+3SD0,05= 1,19. In clear cell papillary 
renal cell carcinomas, the mean ratio was 1,06 (not deleted). 
All clear cell papillary renal cell carcinoma tumours showed no gains of chromosomes 
7 and 17 with single signals ranging from 33 to 43, double signals from 53 to 61 and 
more than two signals from 5 to 15, respectively. 
 
 
 
Figure 11. FISH: disomic pattern of 3p25.  
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VHL gene mutation 
No mutation of coding sequence of the VHL gene was found in epithelial neoplastic  
components in all the clear cell papillary renal cell carcinomas tested. 
 
MLPA findings on methylation and copy number status of VHL 
We performed methylation-specific ligation-dependent probe amplification analysis 
in 4 clear cell papillary renal cell carcinomas. MS-MLPA analysis of FFPE tissue 
DNA samples showed absent or mild methylation of VHL gene in all cases. 
 
Genome wide microRNA expression profiling of clear cell papillary renal cell 
carcinoma  
 Among the 1,205 miRNAs contained in the microarray, 342 mature miRNA 
were differentially expressed between CCPRCC and normal samples with a false 
discovery rate (FDR) of < 10% (supplementary table S1). Table 2 shows the most 
significantly differentially expressed (FDR <5%) miRNAs in CCPRCC compared to 
matched normal renal parenchyma. 
 To identify differentially expressed miRNA between CCPRCC, CCRCC and 
PRCC we analyzed the GSE41282 dataset, containing the expression profile of 6 
CCRCC and 14 PRCC samples with corresponding normal tissue in order to derive 
miRNA gene expression profiles associated with CCRCC and PRCC compared to 
normal kidney. We respectively identified 16 and 2 microRNA moieties as 
differentially expressed (Supplementary Table S2a and S2b). We further analyzed the 
GSE37989 dataset, containing microarray-based profiles of 9 metastatic CCRCC and 
12 primary CCRCC with corresponding non malignant tissue to identify the miRNA 
profiles associated with primary and metastatic clear cell renal carcinoma81; we 
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identified 53 and 20 differentially expressed miRNA, respectively (Supplementary 
Table S3a and S3b). We finally compared our data from CCPRCC to the above datasets. 
Because the publically available datasets were derived from different platforms with 
lower numbers of unique mature miRNA, we performed this cross platform comparison 
using differentially expressed miRNA at a higher significance threshold (FDR of 5%). 
In particular we compared gene expression profiles distinguishing CCPRCC, CCRCC 
and PRCC from normal samples by CAT-plots and Venn diagram, using the results 
from our profiling and the analysis of the GSE41282 dataset. This comparison revealed 
that at the molecular level CCPRCC more closely resembled CCRCC (figure 2 and 
table 3). We used a similar approach to compare our CCPRCC findings with miRNA 
profiles of primary and metastatic CCRCC. This latter analysis showed that at the 
miRNA level CCPRCC more closely resembled primary CCRCC. 
 
Technical validation of microarray findings 
Among the most differentially expressed miRNAs in the microarray experiments, miR-
122, miR-135a and miR-204 were used for technical validation using qRT-PCR. The 
expression levels of these miRNAs was assessed in all 15 CCPRCC samples, including 
the initial 4 cases that were used for microarray experiments. All samples had matched 
normal renal tissue. Our qRT-PCR results were in agreement with the microarray 
findings, validating the robustness of microarray analysis. 
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Figure 12: Consensus among miRNA profiles associated with distinct renal carcinoma 
histotypes and stages. Lines above the 45° diagonal lines correspond to comparisons 
having more agreement than would be expected by chance. Lines in the white area of 
the graph have a probability of agreeing by chance of less than 1E-06. Geneswere 
ranked by t-statistic as obtained fromthe linearmodel analysis. A: CAT curves for the 
following comparisons: miRNA up-regulated and down-regulated in clear cell papillary 
and clear cell tumors; miRNA up-regulated and down-regulated in papillary and clear 
cell papillary tumors. B: CAT curves for the following comparisons: miRNA up-
regulated and down-regulated in clear cell papillary and in primary clear cell tumors; 
miRNA up-regulated and down-regulated in clear cell papillary and clear cells tumor 
metastasis. 
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Figure 13. Technical and independent set validation of miR-122, miR-135a, and miR-
204. A: Average fold changes of samples used for the microarray experiments and qRT-
PCR experiments. B: Relative expression on the 3 miRNAs in all 15 cases. 
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miRNA Name logFC P Value FDR 
Proposed 
function 
Selected validated targets 
miR-210 4.26 4.46E-04 5.38E-04 hypoxamir ISCU, HIF1A, MNT 
miR-34a 2.75 1.06E-02 2.01E-03 oncosuppressor AKT1, PTEN, c-MYC 
miR-122 2.64 1.79E-04 8.96E-03 oncosuppressor 
CDKN2D, SMARCD1, 
CCND1 
miR-21 2.47 4.06E-02 5.43E-03 oncogene PTEN, TIMP3, PDCD4 
miR-34b* 2.20 3.81E-03 1.15E-03 oncosuppressor VEGFA, CREB1, c-MYC 
miR-489 2.16 2.26E-03 2.50E-02 oncosuppressor SRC, COMP, GHRHR 
miR-4284 -2.07 9.74E-04 5.87E-04 - - 
miR-1202 -2.18 2.65E-04 1.06E-02 - - 
miR-135a -2.24 2.22E-04 1.03E-02 oncosuppressor APC, JAK2, FLAP 
miR-1973 -2.61 2.11E-03 2.44E-02 - - 
miR-204 -5.34 2.87E-04 1.06E-02 oncosuppressor VEGFA, RUNX2, E2F3 
 
Table 3. Differentially expressed miRNA in clear cell papillary renal cell carcinoma 
compared to normal matched tissue with log FC>2 and FDR (false discovery rate) <5%. 
 
miRNA Name CCPRCC CCRCC PRCC Selected validated Targets 
hsa-miR-122 UP UP NS SLC7A1, GYS1, GTF2B 
hsa-miR-15a UP UP NS BCL2, VEGFA, PDCD4 
hsa-miR-18a UP UP NS BIM, CTGF, ESR1 
hsa-miR-193a-3p UP UP NS E2F6, PTK2, MCL1 
hsa-miR-1281 UP NS UP - 
hsa-miR-653 UP NS UP - 
hsa-miR-501-3p DOWN NS DOWN - 
hsa-miR-532-3p DOWN NS DOWN - 
hsa-miR-532-5p DOWN NS DOWN RUNX3 
 
Table 4. Differentially expressed miRNAs among clear cell papillary renal cell 
carcinoma, clear cell renal cell carcinoma and papillary renal cell carcinoma.  
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DISCUSSION 
Distinguishing clear cell papillary renal cell carcinoma from clear cell renal cell 
carcinoma is important, since the former has yet to be reported as having a malignant 
potential. As we said noted above, despite having distinctive morphological and 
immunohistochemical characteristics, these two entities can show overlapping features, 
resulting in diagnostic errors. In our study we have demonstrated that CK7 positivity 
and FISH evaluation for 3p deletion, although useful, might not be sufficient for 
distinguishing clear cell papillary renal cell carcinoma from conventional clear cell 
RCC. 
Although clear cell papillary renal cell carcinoma was initially described as a 
multicystic neoplasm with a prominent papillary architecture and composed of cells 
with clear cytoplasm, subsequent series of this tumor have shown a broader spectrum 
of morphological features. Aydin and Williamson highlighted that the papillary 
component is present only in 81% and 65% of cases, emphasizing the branched 
tubular pattern, rather than the papillary pattern, as a distinctive morphological 
characteristic. This latter aspect, however, was often missing in tumors with a 
prominent cystic component 82,83. 
These data underscore the difficulties that may be encountered in 
distinguishing this tumor from papillary renal cell carcinoma with prominent clearing 
of cytoplasm 84, as well as multicystic clear cell renal cell carcinoma and  
conventional clear cell renal cell carcinoma. Such difficulty has been clearly 
demonstrated  by Williamson et al. who reported that 14 clear cell papillary renal cell 
carcinomas were identified from 469 renal cell carcinoma resections performed from 
2004 to 2006 and that the majority of these tumors were originally diagnosed as clear 
cell renal cell carcinoma 82. Their work reinforced the notion that there can be 
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substantial morphologic overlap between clear cell papillary RCC and conventional 
clear cell RCC as only a single tumor with an original diagnosis of papillary renal cell 
carcinoma was reclassified, while only three were originally interpreted as 
multilocular cystic renal cell carcinomas.  
Recently, clear cell papillary renal cell carcinoma-like tumors in patients with 
or without Von Hippel-Lindau disease unrelated to sporadic clear cell papillary renal 
cell carcinoma have been described, highlighting once again the difficulties that one 
might encounter in distinguishing clear cell papillary renal cell carcinoma from 
conventional clear cell renal cell carcinoma 85,86. 
In support of the diagnostic difficulties mentioned above, one of the tumors 
that we selected as clear cell papillary renal cell carcinoma, based on typical 
morphological and immunophenotypical features (diffuse papillary architecture with a 
characteristic arrangement of the nuclei, as well as the presence of branched tubules 
and CK7 positivity), proved to be a conventional clear cell carcinoma with alterations 
of 3p identified by array CGH and VHL mutation. This tumor showed a strong and 
diffuse immunoreactivity for CK7, a marker currently considered as extremely useful 
for differentiating clear cell papillary renal cell carcinoma from clear cell renal cell 
carcinoma 26,87.  
Although the majority of clear cell renal cell carcinomas lack CK7 
immunoexpression, some cases have been reported to be positive for this marker. We 
performed a literature search encompassing a total of 391 cases of clear cell renal cell 
carcinoma and found that 44 (12%) expressed CK7 40,43,44,88. Moreover, in our hands 
we have demonstrated this immunoreactivity in even more (24%) CCRCC. 
 As we demonstrated here, this might lead to misdiagnosis, even in the 
presence of morphologic features typical of clear cell papillary renal cell carcinoma.  
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34βE12  is an antibody that recognizes a different high molecular weight 
cytokeratins (CK) including CK 1, 5, 10 and 14; interestingly, we  found 34βE12 to 
be positive in all but two cases (12/14, 86%), one of these being the CK7-positive 
CCRCC case. Rohan et al. showed 7/9 (78%) of their clear cell papillary renal cell 
carcinoma cases to be positive for this marker; on the other hand, 34βE12 
immunostain was not detected in any of their clear cell renal cell carcinoma tested 
(0/11, 0%) 87 in this study. In our control group of clear cell RCC only 1% of the 
cases showed positivity for this marker. In order to better understand which specific 
cytokeratin is most responsible for the observed 34βE12 positivity in clear cell 
papillary renal cell carcinoma, we evaluated the immunoexpression  of CK1, CK5, 
CK10 and CK14 separately. We found that, among these molecules, CK14 followed 
by CK5 are the most highly expressed high molecular weight cytokeratins in clear cell 
papillary renal cell carcinoma. We also evaluated the expression of  CK14 in TMAs 
containing 150 cases of conventional clear cell renal cell carcinoma: only 2/150 cases 
(1%) stained weakly positive for the marker and  showed the same pattern of 
expression of 34βE12. We therefore suggest that applying 34βE12, or alternatively 
CK14, to the immunohistochemical panel for diagnosing clear cell papillary renal cell 
carcinoma might be useful for distinguishing the latter from conventional clear cell 
renal cell carcinoma. 
Among the most differentially expressed miRNA in CCPRCC, we found miR-
210, miR-122, miR-34a, miR-21, miR-34b* and miR-489 to be upregulated while 
miR-4284, miR-1202, miR-135a, miR-1973 and miR-204 were downregulated 
compared to normal renal parenchyma.   Our microarray findings were further 
validated by qRT-PCR analysis in three of the most differentially expressed miRNAs. 
Our study also revealed that miRNA profile in CCPRCC is more similar to that of 
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CCRCC compared to PRCC. As expected, CCPRCC miRNA profile similarity was 
closer to that of primary than metastatic CCRCC. 
  At the molecular level, CCRCC is characterized by alteration of the VHL gene 
located at chromosome 3p25.3 in the majority of cases. Other common alterations 
involve copy number changes of chromosome 5q and a recently reported mutation of 
the SWI/SNF-related gene PBRM1 89-91. None of these alterations have been seen in 
association with CCPRCC26,87.   
 CAIX is upregulated by HIF. In CCRCC the latter is upregulated as a result of VHL 
loss of function (26, 27). Rohan et al. recently showed normal or elevated VHL 
mRNA expression in CCPRCC compared to normal control87. The authors concluded 
that a wide range of genetic, epigenetic and physiologic factors might be the cause for 
the activation of the HIF pathway that they encountered in this type of tumors. 
Several studies have documented miR-210 to be overexpressed miRNA in CCRCC92. 
MiR-210 is a well known target of HIF and a central player in hypoxia pathway93. A 
recent report also demonstrated that miRNA-210 expression positively modulates HIF 
and correlates with CAIX expression.94 Intriguingly, our finding of miR-210 
upregulation in CCPRCC could be implicating miR-210 in the activation of the 
hypoxia pathway in the absence of VHL. Evidently such hypothesis would require 
verification. 
Among other miRNAs that we found upregulated in our CCPRCC tumors is 
miR-122. It has also been consistently reported to be overexpressed in CCRCC and  
been proposed as a potential regulator of  VHL gene95. A recent study revealed higher 
miR-122 levels in primary compared to metastatic CCRCC81. However, its role in 
CCRCC pathogenesis remains to be fully determined.   
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MiR-34a has been previously shown to be up-regulated in CCRCC96. Using 
CCRCC cell lines, Yamamura et al. demonstrated that miR-34a suppressess c-MYC 
and its complexes and inhibits cell invasion, thus suggesting a role as a tumor 
suppressor in renal cancers97. The pathogenic significance, if any, of our observed 
miR-34a  upregulation in CCPRCC should be further explored . 
  miR-18a was also among miRNAs that we found to be upregulated in 
CCPRCC and CCRCC in comparison with PRCC. The overexpression of miR-18a 
has already been reported in renal cancer98. In breast cancer, miR-18a is implicated in 
negative feedback regulation of ERα  and is upregulated by c-MYC99.  ERα has been 
recently demonstrated to be a proteasomal degradation target of the VHL protein in 
renal carcinoma cell lines100. In VHL-deficient conditions, like CCRCC, ERα is not 
sequestered and induces cell proliferation.  Although in CCRCC setting, miR-18a 
upregulation could be related to ERα, this is less likely the case in CCPRCC given 
their lack of VHL alterations. Whether c-MYC upregulation via miR-210 inhibition of 
its antagonist MNT is responsible for miR-18a in CCPRCC remains to be determined. 
 We found a general down-regulation of miRNAs in CCRCC compared to 
CCPRCC. This is in line with the previously shown stepwise down-regulation of 
microRNA expression from normal to primary and metastatic tumors in renal cancer 
among other tumors81. Among the miRNAs that we found to be consistently down-
regulated in primary and metastatic CCRCC are members of the miR-200 family that 
are thought to regulate the epithelial-mesenchymal transition in human tumorigenesis. 
miR-141 and miR-200c, which have been consistently shown to be down-regulated in 
CCRCC81 were also found to be the down-regulated miRNA in our CCRCC dataset 
analysis.  Their expression in CCPRCC was not significantly different from matched 
normal tissues. Whether the lack of down-regulation of such key microRNA, involved 
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in the incremental progression of malignant biologic behavior of CCRCC, may be in 
part related to the relatively indolent behavior of CCPRCC would require further 
investigation.  
We found miR-135a and miR-204 to be downregulated in CCPRCC. MiR-
135a has been recently reported to act as a tumor suppressor in RCC cell lines by 
targeting c-MYC101. Mikhaylova et al. recently showed that miR-204 is a VHL-
regulated tumor suppressor acting by inhibiting macroautophagy, with LC3B as a 
direct and functional target in CCRCC specimens102.  The mechanisms underlying 
miR-204 downregulation in CCPRCC merits further investigation, specifically in 
regards to the function of VHL.A limitation of the current study is our inability to 
perform functional studies due to the fact that cell lines for CCPRCC are not 
available.  
Finally, we propose a wide morphological and molecular study of clear cell-
papillary RCC to better understand its right collocation in the classification of the 
tumors of the kidney. Now days the frequency of this tumor is about 3%. All the case 
are characterized by a low nuclear grade, small tumor size, no necrosis and low 
mitotic activity. None case of recurrence or metastasis is known. The behavior of 
clear cell-papillary RCC appears to be indolent and this fact rises the idea that 
“carcinoma” could not be the right term for this entity. The fact that its incidence is 
higher in end-stage kidneys can suggest a reactive pathogenesis and this could explain 
the total lack of genetic alterations.  
Sometime in pathology, a proliferation that seems a carcinoma is called 
“carcinoma” even if there is no proof of its malignant potential and it will be called 
“carcinoma” even if a proof of its aggressive behavior will never appear. 
I 
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